NOTE: Please save this file locally before filling in the table, DO NOT work on the file within your internet browser as changes will not be saved. Adobe Acrobat Reader (available free here) is recommended for completion.

ARRIVE The ARRIVE guidelines 2.0: author checklist

The ARRIVE Essential 10

These items are the basic minimum to include in a manuscript. Without this information, readers and reviewers cannot assess the reliability of the findings.

Item		Recommendation	Section/line number, or reason for not reporting
Study design	1	For each experiment, provide brief details of study design including:	Methods line75
		a. The groups being compared, including control groups. If no control group has been used, the rationale should be stated.	Methods line79
		b. The experimental unit (e.g. a single animal, litter, or cage of animals).	Methods line/9
Sample size	2	a. Specify the exact number of experimental units allocated to each group, and the total number in each experiment. Also indicate the total number of animals used.	Methods line103-112
		b. Explain how the sample size was decided. Provide details of any <i>a priori</i> sample size calculation, if done.	Methods line75-80
Inclusion and exclusion criteria	3	a. Describe any criteria used for including and excluding animals (or experimental units) during the experiment, and data points during the analysis. Specify if these	Methods line105-112
		criteria were established <i>a priori</i>. If no criteria were set, state this explicitly.b. For each experimental group, report any animals, experimental units or data points	Methods line105-112
		not included in the analysis and explain why. If there were no exclusions, state so. c. For each analysis, report the exact value of <i>n</i> in each experimental group.	Methods line110-112
Randomisation	4	a. State whether randomisation was used to allocate experimental units to control and treatment groups. If done, provide the method used to generate the randomisation sequence.	Methods line104
		b. Describe the strategy used to minimise potential confounders such as the order of treatments and measurements, or animal/cage location. If confounders were not controlled, state this explicitly.	Methods line104-106
Blinding	5	Describe who was aware of the group allocation at the different stages of the experiment (during the allocation, the conduct of the experiment, the outcome assessment, and the data analysis).	Methods line105-108
Outcome measures	6	a. Clearly define all outcome measures assessed (e.g. cell death, molecular markers, or behavioural changes).	Methods line117-121
		b. For hypothesis-testing studies, specify the primary outcome measure, i.e. the outcome measure that was used to determine the sample size.	Methods line133-135
Statistical methods	7	a. Provide details of the statistical methods used for each analysis, including software used.	Methods line164-170
		b. Describe any methods used to assess whether the data met the assumptions of the statistical approach, and what was done if the assumptions were not met.	Methods line164-170
Experimental animals	8	a. Provide species-appropriate details of the animals used, including species, strain and substrain, sex, age or developmental stage, and, if relevant, weight.	Methods line103-112
		b. Provide further relevant information on the provenance of animals, health/immune status, genetic modification status, genotype, and any previous procedures.	Methods line103-112
Experimental procedures	9	For each experimental group, including controls, describe the procedures in enough detail to allow others to replicate them, including:	Methods line74-102
		a. What was done, how it was done and what was used.	line74-102
		b. When and how often.	line74-102
		c. Where (including detail of any acclimatisation periods).d. Why (provide rationale for procedures).	line74-102
Results	10	For each experiment conducted, including independent replications, report:	Results line256-261
		a. Summary/descriptive statistics for each experimental group, with a measure of variability where applicable (e.g. mean and SD, or median and range).b. If applicable, the effect size with a confidence interval.	Results line256-261

The Recommended Set

These items complement the Essential 10 and add important context to the study. Reporting the items in both sets represents best practice.

Item		Recommendation	Section/line number, or reason for not reporting
Abstract	11	Provide an accurate summary of the research objectives, animal species, strain and sex, key methods, principal findings, and study conclusions.	Methods line105-112
Background	12	a. Include sufficient scientific background to understand the rationale and context for the study, and explain the experimental approach.	Methods line70-73
		 Explain how the animal species and model used address the scientific objectives and, where appropriate, the relevance to human biology. 	Methods line105-112
Objectives	13	Clearly describe the research question, research objectives and, where appropriate, specific hypotheses being tested.	Introduction line 50-59
Ethical statement	14	Provide the name of the ethical review committee or equivalent that has approved the use of animals in this study, and any relevant licence or protocol numbers (if applicable). If ethical approval was not sought or granted, provide a justification.	line 323-326
Housing and husbandry	15	Provide details of housing and husbandry conditions, including any environmental enrichment.	Methods line105-112
Animal care and monitoring	16	 Describe any interventions or steps taken in the experimental protocols to reduce pain, suffering and distress. 	Methods line105-112
		b. Report any expected or unexpected adverse events.	Methods
		c. Describe the humane endpoints established for the study, the signs that were monitored and the frequency of monitoring. If the study did not have humane endpoints, state this.	line105-112 Methods line105-112
Interpretation/ scientific implications	17	a. Interpret the results, taking into account the study objectives and hypotheses, current theory and other relevant studies in the literature.	Results 174-184
		b. Comment on the study limitations including potential sources of bias, limitations of the animal model, and imprecision associated with the results.	Discussion line 304-306
Generalisability/ translation	18	Comment on whether, and how, the findings of this study are likely to generalise to other species or experimental conditions, including any relevance to human biology (where appropriate).	Discussion line 300-307
Protocol registration	19	Provide a statement indicating whether a protocol (including the research question, key design features, and analysis plan) was prepared before the study, and if and where this protocol was registered.	Method line177
Data access	20	Provide a statement describing if and where study data are available.	nc,we will contimue rhe follow-up research
Declaration of interests	21	a. Declare any potential conflicts of interest, including financial and non-financial. If none exist, this should be stated.	line 321-322
		 b. List all funding sources (including grant identifier) and the role of the funder(s) in the design, analysis and reporting of the study. 	line 319-320

Article information: https://dx.doi.org/10.21037/jgo-21-819

